{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"20.1","value":"14.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Kaplan-Meier estimates will be calculated and log-rank tests will be employed when certain comparisons are needed. Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.","dispersionType":"Full Range","groups":[{"description":"Dose Level 7; Bendamustine 90mg/m2, ABT-888 400mg BID","id":"OG000","title":"All Study Participants"}],"paramType":"MEDIAN","populationDescription":"Participants treated on Dose Level 7 make up the cohort expansion of VBR in participants with CD20+ B-cell lymphoma.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression-free Survival Using RECIST Version 1.1 (Phase IIa)","type":"SECONDARY","unitOfMeasure":"Months"}